ProKidney has one asset: rilparencel, an autologous renal cell therapy injected bilaterally into the kidneys to slow CKD progression. One trial that matters: PROACT 1, a randomized sham-controlled Phase 3. One date: Q2 2027. Everything else is setup.

The market at $2.08 implies a ≈23% Phase 3 success probability, back-solved from the scenario distribution. The case here is that probability is closer to 40% — a gap driven by two recent derisking events the market hasn't fully absorbed. The GLP-1 competitive picture is real and worsening. The cash runway is tight. Those risks are in the price. The question is whether the clinical signal is better than 23%.

What the 10-K Shows

The FY2025 10-K filed March 18, 2026 has two material signal items that are newer than market consensus.

FDA Type B meeting, Q3 2025. FDA formally confirmed that eGFR slope is a valid surrogate endpoint for accelerated approval BLA submission, and that PROACT 1 can serve as both the accelerated approval basis and the confirmatory study for full approval. This meeting happened quietly — no press release fanfare, buried in the filing. The regulatory path is now blueprint-level certain conditional on Phase 3 data. RMAT designation is confirmed. The company has burned boats on the endpoint question.

Phase 2 REGEN-007, published CJASN early 2026. Group 1 (n=24, matching PROACT 1 dosing): eGFR slope improved 78% from -5.8 to -1.3 mL/min/1.73m²/year, 4.6 mL/min/1.73m²/year absolute, p<0.001. In the PROACT 1 inclusion criteria subgroup (n=15): 85% improvement, 5.5 mL/min/1.73m²/year. No rilparencel-related serious adverse events. Published in a peer-reviewed nephrology journal after presentation as a late-breaking trial at ASN Kidney Week 2025. This is the freshest clinical evidence available — market has not fully digested it.

What hasn't changed: Cash is declining on schedule ($395M → $270M year-over-year), burn is improving ($120M operating cash in 2025 vs $126M in 2024), and the timeline is tight. The company's own guidance puts runway at mid-2027. Q2 2027 Phase 3 topline and mid-2027 cash exhaustion are within the same quarter. There is no slack.

Factor Decomposition

This is a clinical binary. Statistical factor regression is near-meaningless for a single-asset company with 527% idiosyncratic vol. The useful decomposition is thesis factors — the independent drivers that determine which scenario materializes.

Factor 1 — Clinical Efficacy [70% of return distribution]

Does rilparencel show statistically significant eGFR slope improvement vs. sham control? Phase 2 data is encouraging but was single-arm before/after. The sham-controlled Phase 3 design is the test that matters. The most common failure mode in CKD cell therapy is Phase 2 effect sizes that don't survive blinding — placebo effect on eGFR slope is documented, and regression to the mean in n=24 trials is real.

Our P(Phase 3 positive): 40%. Market implied: ≈23%. Edge: +17 percentage points. Confidence in edge: low-medium. Clinical binaries are inherently uncertain — the edge here is that the FDA derisking (Type B meeting) and the CJASN publication are recent and underweighted, not that we can predict Phase 3 outcomes from Phase 2 data.

Factor 2 — Regulatory Acceptance [largely resolved]

FDA answered this question in the Q3 2025 Type B meeting. eGFR slope is the endpoint. PROACT 1 is the confirmatory study. RMAT is the pathway. Residual risks: FDA policy environment shift (DOGE-era FDA slowdown is a latent tail), BLA manufacturing deficiency. P(FDA accepts positive data): 90%+. No edge here — it's priced in once you've read the filing.

Factor 3 — GLP-1 Competitive Pressure [independent bearish force]

This is the one truly independent factor that degrades value even if the biology works.

Ozempic received FDA approval for CKD in T2D patients on January 28, 2025 — PROK's exact target population. Based on the FLOW trial: 24% relative risk reduction, 4.9% absolute risk reduction over three years. NVO is not holding this label passively. From Q2 2025 earnings (David Moore, EVP US Operations): "Full chronic kidney disease indication yet fully realized. Allows reach additional patient segment Type-2 diabetes population. Continue invest commercial activities label updates further market penetration." NVO is actively building nephrology as a new prescriber channel, adding to the endocrinology/PCP base.

LLY has TREASURE-CKD (NCT05536804) — a dedicated Phase 3 for tirzepatide in CKD with or without T2D. ASN Kidney Week 2025 SURPASS-CVOT sub-analysis already shows tirzepatide cutting eGFR decline from -7.2 to -3.0 mL/min/1.73m²/year vs. dulaglutide (58% improvement). This is a class effect, not a single-competitor problem.

The bull counterargument is mechanism differentiation: GLP-1 works via hemodynamic and anti-inflammatory pathways, rilparencel targets tubular cell regeneration. These could be additive. Travere Therapeutics (IgAN/FSGS) doesn't flag GLP-1 as a competitive threat, suggesting nephrology community views mechanism-specific therapies as complementary. But Travere treats structurally different CKD than PROK's diabetic population — the absence isn't fully dispositive.

We have bearish edge here. Market prices the $10 bull case assuming unchanged TAM. GLP-1 penetration into nephrology compresses that even in the win scenario. Our read: 60% probability GLP-1 meaningfully shrinks rilparencel's addressable T2D+CKD market by the time PROK could reach commercial scale (2029 earliest).

Factor 4 — Capital / Survival [independent path risk]

$270M liquidity, ≈$120M annual burn, mid-2027 runway. PROACT 1 topline Q2 2027 — the math barely works if the trial runs on schedule. ATM: $175M remaining capacity with Jefferies. At $2.08, that's 84M new shares — 28% dilution to existing holders. Post-readout, the company needs another $150-200M for BLA prep and pre-commercial activities regardless of Phase 3 outcome.

The dangerous interaction: trial delay (enrollment gap, safety hold, site issue) simultaneously degrades Phase 3 probability perception AND forces an emergency capital raise at the worst possible moment. These are correlated negatives. Enrollment count for PROACT 1 was not disclosed in the 10-K. Target is ≈470 patients with ≈360 needed for the efficacy analysis set. We don't know where enrollment stands today.

No edge on this factor — it's arithmetic. What it creates is a monitoring priority: watch every 8-K for enrollment updates.

Factor 5 — Commercial Manufacturing Scalability [conditional, long-dated]

Each rilparencel treatment requires kidney biopsy, autologous cell culture at Winston-Salem, cryopreservation, and bilateral renal injection. More logistically complex than IV CAR-T infusion. PROK operates its own facility (not CDMO-dependent), which provides process control but no backup manufacturer. The GMP pause in 2023/early 2024 was remediated without safety events — EU GMP compliance (QP Declaration) restored July 2024. Cross-ticker analysis shows this pattern is industry-wide: Atara received a CRL for tab-cel (GMP compliance, January 2025), CARsgen had three programs on clinical hold after CMC inspection (lifted October 2024), Allogene had manufacturing failures in autologous programs. PROK's pause was industry-normal, not a red flag.

The structural commercial risk — thousands of patients per year at viable per-patient economics — remains unproven across the entire autologous cell therapy space. No company has done it at scale. This doesn't affect the Q2 2027 binary, but it affects what the $10 bull case is actually worth if achieved.

What Market Is Pricing vs. What We Think

Back-solved from $2.08 using the scenario distribution (bull 35%→$10, base 35%→$3.50, bear 30%→$0.50, with Phase 3 success split 60% bull / 40% base):

EV = p × [0.60×$10 + 0.40×$3.50] + (1-p) × $0.50 = $2.08
p = ($2.08 - $0.50) / ($7.40 - $0.50) ≈ 23%

Market implies 23% Phase 3 success. We estimate 40%. The edge is +17 percentage points, and it needs to be right — not correct to within 5pp, right. At 25% we barely break even.

Sum-of-parts check: ATM-diluted cash floor is $1.16/share ($445M cash post-full-ATM / 385M diluted shares). At $2.08 you're paying $0.92 for the clinical option. That option is worth $2.10 at our probability estimate (40% × ($7.40-$1.16) + 60% × ($0.50-$1.16)). Intrinsic value: $3.26 vs $2.08 current — a 36% discount to sum-of-parts.

Sensitivity: the position is in the money at any Phase 3 success probability above 23%. At 30% (halfway between our estimate and market), EV is $2.57 — still above current. We need to be badly wrong about the clinical signal before this loses money on EV.

Entry, Sizing, Catalysts

Entry zone: $1.50–$2.25. Current $2.08 is in zone. The $175M ATM creates a structural ceiling — above ≈$2.50, PROK has economic incentive to issue shares, creating persistent supply pressure. Don't confuse ATM-suppressed prices with better fundamentals. Hard ceiling for new entries at $3.50, which is the base case scenario price; above that the implied success probability exceeds our estimate.

Sizing: Kelly on the 3-case distribution gives full Kelly 6-8%, half-Kelly 3-4%. Discount for GLP-1 competitive headwind, correlated delay-dilution path risk, and concentration limits: 1-2% final. The EV is strong — the position is small because idio vol is 527% and the 10th percentile path is -76%. Size to survive the bear case.

Catalyst calendar (ordered by impact):

1. PROACT 1 enrollment completion 8-K — 6-12 months, 38% probability. If filed, locks the Q2 2027 timeline and removes the delay-capital correlation risk. Stock likely re-rates to $3-4. Buy before this. The intermediate catalyst that closes the entry window.

2. Strategic partnership ≥$50M — 18% probability before Phase 3 readout. Would transform capital structure (non-dilutive), validate commercial thesis, likely gap the stock to $5-8. Cannot position for specifically; if announced, reassess thesis and sizing.

3. LLY TREASURE-CKD Phase 3 results — 2026-2027, timing unclear. Strong tirzepatide CKD data intensifies competitive risk; weak data reduces it. Watch LLY 8-Ks.

4. Phase 3 topline data Q2 2027 — The binary. Bull +381%, base +68%, bear -76%.

Exit triggers: 8-K disclosing PROACT 1 hold, site suspension, or safety issue — exit at any price. DSMB-triggered suspension — same. Emergency equity raise below $1.00/share signals capital crisis. Everything else — macro selloff, ATM-driven price suppression, GLP-1 competitive news — hold through.

What Would Change the View

More bullish: Partnership/licensing deal providing non-dilutive capital. PROACT 1 enrollment completion disclosed (removes timeline risk). Short interest declining meaningfully from the informed-short cohort. Second insider or board member adding at current prices. LLY TREASURE-CKD disappoints.

More bearish: Enrollment delay or site closure disclosed via 8-K. FDA manufacturing inspection letter. Sub-$1.00 share raise. NVO CKD TRx data showing rapid nephrology penetration (closes complementarity argument). DSMB-initiated hold.

The co-founder signal: Chairman Pablo Legorreta (Tolerantia LLC) bought 3.82M shares in June 2025 (≈$7.95M) and 532K shares in February 2025 (≈$1.1M) — $9M total open market purchase. He co-founded ProKidney LLC before the SPAC transaction, not a post-IPO governance appointment. This is a founder buying more of his own company as Phase 3 approaches. Cross-checking Royalty Pharma (RPRX), which Legorreta also chairs: RPRX has zero CKD royalty exposure (confirmed via 10-K and four quarters of transcripts). This is not deal-flow intelligence from RPRX — it is founder conviction. Still the highest single activation signal in the thesis.

Conclusion

The thesis is a clinical binary with the market mispricing success probability at 23% vs our 40%. The two recent derisking events — FDA's Q3 2025 Type B meeting endpoint confirmation and the CJASN Phase 2 publication — are underweighted. The GLP-1 competitive threat is real and has cross-ticker corroboration; it degrades the commercial value of the success case but doesn't change Phase 3 probability. The cash cliff and ATM overhang create path dependency risk that's independent of biology.

This is not a conviction overweight. The Sharpe on any clinical binary is low regardless of edge magnitude. It's a 1-2% survival-sized speculative position, sized to matter if right and survive if wrong. The window is 15 months. The enrollment completion 8-K is the most important intermediate monitoring item — if the company discloses it before Q4 2026, the entry window closes.

Evidence